Journal article

Variable CD34( ) recovery of cryopreserved allogeneic HPC products: transplant implications during the COVID-19 pandemic

Duncan Purtill, Vicki Antonenas, Paul Chiappini, Daochen Tong, Elizabeth O'Flaherty, Ashish Bajel, Karieshma Kabani, Stephen Larsen, Suikeat Tan, Cheryl Hutchins, David J Curtis, Glen A Kennedy, Anne-Marie Watson, LiJun Bai, Matthew Greenwood, David J Gottlieb, Nada Hamad

Blood Advances | AMER SOC HEMATOLOGY | Published : 2020


Donor registries and transplantation societies recommend cryopreservation of unrelated donor hemopoietic progenitor cell (HPC) products before the recipient commences conditioning therapy to mitigate the donor and travel risks associated with the COVID-19 pandemic. However, little is known regarding the postthaw quality of such allogeneic products or the effect of precryopreservation storage and processing on these characteristics. We investigated the postthaw CD34+ cell recovery and viability of 305 allogeneic HPC products cryopreserved at 9 laboratories across Australia. Median postthaw CD34+ cell recovery was 76% and ranged from 6% to 122%. Longer transit time before cryopreservation, whi..

View full abstract